TABLE 3.
Univariate and multivariate regression analyses for ACM after PSM
| Characteristic | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Age | 1.025 | 1.014‐1.036 | <.001* | 1.021 | 1.010‐1.033 | <.001* |
| Gender | ||||||
| Female | Ref. | .041* | Ref. | .054 | ||
| Male | 0.535 | 0.293‐0.976 | 0.551 | 0.300‐1.012 | ||
| Race | ||||||
| White | Ref. | .172 | ||||
| Black | 1.007 | 0.610‐1.662 | .977 | |||
| AI | 1.127 | 0.281‐4.528 | .866 | |||
| API | 0.463 | 0.254‐0.844 | .012* | |||
| Unknown (n = 2) | ||||||
| Marital status | ||||||
| Married | Ref. | .032* | Ref. | .100 | ||
| No | 1.315 | 1.055‐1.639 | .015* | 1.276 | 1.015‐1.605 | .037* |
| Unknown | 0.536 | 0.133‐2.154 | .379 | 0.733 | 0.181‐2.958 | .662 |
| Primary tumor site | ||||||
| Trigone of bladder | Ref. | .813 | ||||
| Dome of bladder | 0.804 | .470 | ||||
| Lateral wall of bladder | 0.780 | .269 | ||||
| Anterior wall of bladder | 0.416 | .101 | ||||
| Posterior wall of bladder | 0.741 | .257 | ||||
| Bladder neck | 0.540 | .145 | ||||
| Ureteric orifice | 0.597 | .334 | ||||
| Urachus (n = 2) | ||||||
| Overlapping lesion of bladder | 0.726 | 0.470‐1.120 | .148 | |||
| Bladder, NOS | 0.809 | 0.541‐1.211 | .303 | |||
| Histology | ||||||
| Transitional cell carcinoma | Ref. | .040* | Ref. | .084 | ||
| Squamous cell carcinoma | 0.382 | 0.143‐1.023 | .056 | 0.381 | 0.141‐1.029 | .057 |
| Other types | 1.451 | 0.925‐2.277 | .105 | 1.331 | 0.796‐2.227 | .276 |
| Pathological T stage | ||||||
| T0‐Tis‐Ta‐T1 | Ref. | <.001* | Ref. | <.001* | ||
| T2 | 1.656 | 1.123‐2.442 | .011* | 1.552 | 1.051‐2.292 | .027 |
| T3 | 3.307 | 2.243‐4.875 | <.001* | 2.584 | 1.732‐3.854 | <.001* |
| T4 | 4.520 | 2.939‐6.951 | <.001* | 3.718 | 2.394‐5.774 | <.001* |
| Tx/NA | 2.642 | 0.932‐7.487 | .068 | 0.647 | 0.135‐3.098 | .586 |
| Pathological N stage | ||||||
| N0 | Ref. | <.001* | Ref. | <.001* | ||
| N1 | 2.307 | 1.739‐3.062 | <.001* | 1.577 | 1.171‐2.123 | .003* |
| N2 | 2.885 | 2.144‐3.882 | <.001* | 2.401 | 1.768‐3.261 | <.001* |
| N3 (n = 0) | ||||||
| Nx/NA | 2.007 | 0.947‐4.252 | .069 | 3.284 | 1.050‐10.270 | .041* |
| Pathological M stage | ||||||
| M0 | Ref. | .024* | Ref. | .982 | ||
| M1 | 1.970 | 1.211‐3.206 | .006* | 0.975 | 0.571‐1.664 | .926 |
| Mx/NA | 1.127 | 0.466‐2.724 | .791 | 0.849 | 0.128‐5.644 | .866 |
| Grade | ||||||
| I | Ref. | .511 | ||||
| II | 0.615 | 0.204‐1.853 | .388 | |||
| III | 0.746 | 0.275‐2.023 | .564 | |||
| IV | 0.872 | 0.325‐2.343 | .786 | |||
| Unknown | 0.822 | 0.275‐2.459 | .726 | |||
| Lymphadenectomy | ||||||
| No | Ref. | .961 | ||||
| Yes | 0.956 | 0.525‐1.743 | .884 | |||
| Others | 0.806 | 0.179‐3.639 | .780 | |||
| Urinary diversion | ||||||
| Ileal conduit | Ref. | .001* | Ref. | <.001* | ||
| Orthotopic neobladder | 0.705 | 0.576‐0.862 | 0.671 | 0.548‐0.823 | ||
| Adjuvant radiation | ||||||
| No | Ref. | .002* | Ref. | .033* | ||
| Yes | 3.523 | 1.567‐7.919 | 2.526 | 1.080‐5.908 | ||
| Adjuvant chemotherapy | ||||||
| No | Ref. | .098 | ||||
| Yes | 1.187 | 0.969‐1.455 | ||||
Abbreviations: ACM, all‐cause mortality; AI, American Indian/Alaskan Native; API, Asian/Pacific Islander; CI, confidence interval; HR, hazard ratio; NA, not available; NOS, not otherwise specified; PSM, propensity score matching; Ref., reference.
*
Statistically significant.